Loading...
An Adaptive Control Scheme for Interleukin-2 Therapy.
Khailaie, Sahamoddin Montaseri, Ghazal Meyer-Hermann, Michael
Khailaie, Sahamoddin
Montaseri, Ghazal
Meyer-Hermann, Michael
An error occurred retrieving the object's statistics
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2020-10-12
Submitted date
Other Titles
Abstract
Regulatory T cells (Treg) are suppressor cells that control self-reactive and excessive effector conventional T helper cell (Tconv) responses. Breakdown of the balance between Tregs and Tconvs is a hallmark of autoimmune and inflammatory diseases. Interleukin-2 (IL-2) is a growth factor for both populations and subtle leverage to restore the healthy immune balance in IL-2 therapy. By using a mechanistic mathematical model, we introduced an adaptive control strategy to design the minimal therapeutic IL-2 dosage required to increase and stabilize Treg population and restrict inflammatory response. This adaptive protocol allows for dose adjustments based on the feedback of the immune kinetics of the patient. Our simulation results showed that a minimal Treg population was required to restrict the transient side effect of IL-2 injections on the effector Tconv response. In silico results suggested that a combination of IL-2 and adoptive Treg transfer therapies can limit this side effect.
Citation
iScience. 2020 Oct 12;23(11):101663. doi: 10.1016/j.isci.2020.101663.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
2589-0042
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International